Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Cohance Lifesciences Community
NSEI:SUVENPHAR Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Create a narrative
Cohance Lifesciences
Popular
Undervalued
Overvalued
Community Investing Ideas
Cohance Lifesciences
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Acquisitions Will Expand Opportunities In ADCs And Oligonucleotides
Key Takeaways Strategic acquisitions and entry into high-growth segments enhance revenue and margins by tapping into high-value markets like oligonucleotides and ADCs. Diversification and expansion into specialty segments with differentiated technology and M&A bolster competitive advantage and drive predictable, accelerated growth. Strategic acquisition reliance and volatile demand may strain cash flow, impacting financial stability, margins, and long-term earnings if expected synergies aren't realized.
View narrative
₹1.40k
FV
22.5% undervalued
intrinsic discount
65.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
13 days ago
author updated this narrative
Your Valuation for
SUVENPHAR
SUVENPHAR
Cohance Lifesciences
Your Fair Value
₹
Current Price
₹1.08k
18.6% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
33b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹32.6b
Earnings ₹8.7b
Advanced
Set Fair Value